Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The phase I study is to determine the maximum tolerated dose and dose limiting toxicity of docetaxel and nedaplatin prescribed twice weekly in combination with concurrent chest radiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
DRUG: Docetaxel|DRUG: Nedaplatin|RADIATION: chest radiation
Occurrence of dose limiting toxicity, From start of week 1 to 2 weeks after end of combination treatment (combination treatment = 6.5 weeks)|Maximum tolerated dose, From start of week 1 to 2 weeks after end of combination treatment (combination treatment = 6.5 weeks)
Occurrence and severity of adverse events, From start of week 1 to 6 weeks after end of combination treatment (combination treatment = 6.5 weeks)|Clinical response rate, 8 weeks after end of combination treatment|Dynamic plasma concentration of docetaxel and nedaplatin, From start of week 1 to the end of combination treatment (6.5 weeks)
The phase I study is to determine the maximum tolerated dose and dose limiting toxicity of docetaxel and nedaplatin prescribed twice weekly in combination with concurrent chest radiotherapy in patients with locally advanced esophageal squamous cell carcinoma.